Noninvasive tests for liver fibrosis

Seminars in Liver Disease

Volumn 26, Issue 4, 2006, Pages 337-347

  Mukherjea, Sandeep ^a,b   Sorrell, Michael F ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Section of Gastroenterology and Hepatology   (United States)

Author keywords

Fibrosis; Noninvasive tests; Radiological markers; Serological markers

Indexed keywords

BIOCHEMICAL MARKER;

ARTIFICIAL INTELLIGENCE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE SEVERITY; EXTRACELLULAR MATRIX; GENE IDENTIFICATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; LIVER CIRRHOSIS; LIVER FIBROSIS; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; RADIODIAGNOSIS; REVIEW; SERODIAGNOSIS; STATISTICAL ANALYSIS;

BIOLOGICAL MARKERS; DIAGNOSTIC IMAGING; HUMANS; LIVER CIRRHOSIS;

EID: 33750366551     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-951598     Document Type: Review

References (96)

1. Cholongitas E, Senzolo M, Standish R, et al. A systematic review of the quality of liver biopsy specimens. Am J Clin Pathol 2006;125:710-721
2. Regev A, Berho M, Jeffers LJ, et al. Sampling errors and intraobserver variation in liver biopsy in patients with chronic hepatitis C infection. Am J Gastroenterol 2002;97:2614-2618
3. Kelleher TB, Afdhal N. Noninvasive assessment of liver fibrosis. Clin Liver Dis 2005;9:667-683
4. Friedman SL, Bansal MB. Reversal of hepatic fibrosis: fact or fantasy. Hepatology 2006;43:S82-S88
5. Tsukada S, Parsons CJ, Rippe RA. Mechanisms of liver fibrosis. Clin Chim Acta 2006;364:33-60
6. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-526
7. Adinolfi LE, Giordano MG, Andreana A, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 2001;113:590-595
8. Kamimoto Y, Horiuchi S, Tanase S, Morino Y. Plasma clearance of intravenously injected aspartate aminotransferase isozymes: evidence for preferential uptake by sinusoidal liver cells. Hepatology 1985;5:367-375
9. Lackner C, Struber G, Liegl B, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005;41:1376-1382
10. Sebastiani G, Vario A, Guido M, et al. Stepwise combination algorithm of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006;44:686-693
11. Le Calvez S, Thabut D, Messous D, et al. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C. Hepatology 2004;39:862-863
12. Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36:986-992
13. Macias J, Giron-Gonzalez JA, Gonsalez-Serrano M, et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut 2006;55:409-414
14. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis on patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-1075
15. Myers RP, Tainturier M-H, Ratziu V, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003;39:222-230
16. Rossi E, Adams LA, Prins A, et al. Validation of the Fibrotest Biochemical Markers Score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003;49:450-454
17. Poynard T, Zoulim F, Ratziu V, et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 2005;100:1970-1980
18. Thuluvath PJ, Krok KL. Noninvasive markers of liver fibrosis for longitudinal assessment of fibrosis in chronic liver disease: are they ready for prime time? Am J Gastroenterol 2005;100:1981-1983
19. Shiffman ML, Hofmann CM, Contos MJ, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999;117:1164-1172
20. Naveau S, Raynard B, Ratziu V, et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005;3:167-174
21. Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006;6:6. Available at: http://www.biomedcentral.eom/1471-230X/6/6. Accessed May 21, 2006
22. Poynard T, McHutchinson J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003;38:481-492
23. Imbert-Bismut F, Messous D, Thibaut V, et al. Intralaboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med 2004;42:323-333
24. Thabut D, Trabut JB, Massard J, et al. Non-invasive diagnosis of large esophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study. Liver Int 2006;26:271-278
25. Nandi A, Estess P, Siegelman MH. Hyaluronan anchoring and regulation on the surface of vascular endothelial cells is mediated through the functionally active form of CD44. J Biol Chem 2000;275:14939-14948
26. Wong VS, Hughes V, Trull A, et al. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C infection. J Viral Hepat 1998;5:187-192
27. McHutchison JG, Blatt LM, de Medina M, et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol 2000;15:945-951
28. Halfon P, Bourliere M, Peneranda G, et al. Accuracy of hyaluronic acid for predicting liver fibrosis stages in patients with hepatitis C. Comp Hepatol 2005;4:6. Available at: http://www.comparative-hepatology.com/content/4/1/6. Accessed April 10, 2006
29. Fraser JR, Gibson PR. Mechanisms by which food intake elevated circulating levels of hyaluronan in humans. J Intern Med 2005;258:460-466
30. Vrochides D, Papanikalaou V, Pertoft H, Antoniades AA, Heldin P. Biosynthesis and degradation of hyaluronan by nonparenchymal liver cells during liver regeneration. Hepatology 1996;23:1650-1655
31. Montazeri G, Estakhri A, Mohamednejad M, et al. Serum hyaluronates as a non-invasive marker of hepatic fibrosis and inflammation in HbeAg-negative chronic hepatitis B. BMC Gastroenterol 2005;5:32
32. Poynard T, Imbert-Bismut F, Ratziu V, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 2002;9:128-133
33. Lebensztejn DM, Kaczmarski M, Sobaniec-Lotowska M et al. Serum laminin-2 and hyaluronan predict severe liver fibrosis in children with hepatitis B. Hepatology 2004;39:868-869
34. Zeng MD, Lu LG, Mao YM, et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a non-invasive model. Hepatology 2005;42:1437-1445
35. Suzuki A, Anjulo P, Lymp J, et al. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 2005;25:779-786
36. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-1362
37. Walsh KM, Fletcher A, MacSween RN, Morris AJ. Comparison of assays for N-amino terminal propeptide of type III procollagen in chronic hepatitis C by using receiver operating characteristics. Eur J Gastroenterol Hepatol 1999;11:827-831
38. Guechot J, Laudat A, Loria A, et al. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996;42:558-563
39. Leonardi S, La Spina M, La Rosa M, Schiliro G. Prolylhydroxylase and procollagen type III in long-term survivors of acute lymphoblastic leukemia (ALL): a biochemical approach to HCV-related liver disease. Med Pediatr Oncol 2003;41:17-20
40. Chalmers RJ, Kirby B, Smith A, et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol 2005;152:444-450
41. Zachariae H, Heickendorff L, Sogaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10 year follow-up. Br J Dermatol 2001;144:100-103
42. Serejo F, Costa A, Gouveia Olivera A, et al. Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III. Dig Dis Sci 2001;46:1684-1689
43. Ponomarenko Y, Anna Leo M, Kroll W, Lieber CS. Effects of alcohol consumption on eight circulating markers of liver fibrosis. Alcohol Alcohol 2002;37:252-255
44. Iredale JP. Hepatic stellate cell behaviour during resolution of liver injury. Semin Liver Dis 2001;21:427-436
45. Murphy FR, Issa R, Zhou X, et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 2002;277:11069-11076
46. Walsh KM, Timms P, Campbell S, et al. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci 1999;44:624-630
47. Boeker KH, Haberkorn CI, Michels D, et al. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta 2002;316:71-81
48. Leroy V, Monier F, Bottari S, et al. Circulating matrix metalloproteinases 1,2,9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 2004;99:271-279
49. Lebensztejn DM, Sobaniec-Lotowska ME, Bauer M, et al. Serum fibrosis markers as predictors of an anti-fibrotic effect of interferon alfa in children with chronic hepatitis B. Eur J Gastroenterol Hepatol 2005;17:843-848
50. Johansen JS, Christoffersen P, Moller S, et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000;32:911-920
51. Bigg HF, Wait R, Rowan AD, Cawston TE. The mammalian chitinase-like lectin, YKL-40, binds specifically to type I collagen and modulates the rate of type I collagen fibril formation. J Biol Chem 2006;281:21082-21095
52. Saitou Y, Shiraki K, Yamanaka Y, et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 2005;11:476-481
53. Nojgaard C, Johansen JS, Christensen E, et al. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol 2003;39:179-186
54. Nunes D, Fleming C, Offner G, et al. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr 2005;40:538-544
55. Johansen JS, Jensen BV, Roslind A, et al. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 2006;15:194-202
56. Nordenbaek C, Johansen JS, Haldberg P, et al. High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement. Scand J Rheumatol 2005;34:293-297
57. Koutroubakis IE, Petinaki E, Dimoulios P, et al. Increased serum levels of YKL-40 in patients with inflammatory bowel disease. Int J Colorectal Dis 2003;18:254-259
58. Rathcke CN, Johansen JS, Vestergaard H. YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflamm Res 2006;55:53-59
59. Patel K, Gordon SC, Jacobson I, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004;41:935-942
60. Poordad FF. FIBROSPECT II: a potential noninvasive test to assess hepatic fibrosis. Expert Rev Mol Diagn 2004;4:593-597
61. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127:1704-1713
62. Bissell DM. Assessing fibrosis without a liver biopsy: are we there yet? Gastroenterology 2004;127:1847-1849
63. Kelleher TB, Mehta SH, Bhaskar RM, et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 2005;43:78-84
64. Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005;51:1867-1873
65. Cales P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005;42:1373-1381
66. Benlloch S, Berenguer M, Prieto M, et al. Prediction of fibrosis in HCV-infected liver transplant recipients with a simple noninvasive index. Liver Transpl 2005;11:456-462
67. Lee VS. Science to practice: Can MR imaging replace liver biopsy for the diagnosis of early fibrosis? Radiology 2006;239:309-310
68. Colletta C, Smirne C, Fabris C, et al. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 2005;42:838-845
69. Corpechot C, El Naggar A, Poujol-Robert A, et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006;43:1118-1124
70. Masaki N, Imamura M, Kikuchi Y, Oka S. Usefulness of elastometry in evaluating the extents of liver fibrosis in hemophiliacs coinfected with hepatitis C and human immunodeficiency virus. Hepatol Res 2006;35:135-139
71. Laharie D, Zerbib F, Adhoute X, et al. Diagnosis of liver fibrosis by transient elastography (Fibroscan) and noninvasive methods in Crohn's disease patients treated with methotrexate. Aliment Pharmacol Ther 2006;23:1621-1628
72. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-350
73. McClain CJ, Cohen DA. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 1989;9:349-351
74. McClain C, Barve S, Joshi-Barve S, et al. Dysregulated cytokine metabolism, altered hepatic methionine metabolism and proteasome dysfunction in alcoholic liver disease. Alcohol Clin Exp Res 2005;29:180S-188S
75. Kanzler S, Baumann M, Schirmacher P, et al. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J Viral Hepat 2001;8:430-437
76. Ben-Ari Z, Pappo O, Druzd T, et al. Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation. Cytokine 2004;27:7-14
77. Akpolat N, Yahsi S, Godekmerdan A, et al. Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B. World J Gastroenterol 2005;11:3260-3263
78. Dev A, Patel K, Conrad A, et al. Relationship of smoking and fibrosis in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2006;4:797-801
79. Musso G, Gambino R, Biroli G, et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2005;100:2438-2446
80. Musso G, Gambino R, Durazzo M, et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 2005;42:1175-1183
81. Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004;40:46-54
82. Bahcecioglu IH, Yalniz M, Ataseven H, et al. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with non-alcoholic steatohepatitis. Hepatogastroenterology 2005;52:1549-1553
83. Day CP. Genetic studies to identify hepatic fibrosis genes and SNFs in human populations. Methods Mol Med 2005;117:315-331
84. Patel K, Norris S, Lebeck L, et al. HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C. Hepatology 2006;43:241-249
85. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003;37:493-503
86. Huang H, Shiffman ML, Cheung RC, et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with hepatitis C. Gastroenterology 2006;130:1679-1687
87. Blanton RE, Salam EA, Ehsan A, King CH, Goddard KA. Schistosomal hepatic fibrosis and the interferon gamma receptor: a linkage analysis using single-nucleotide polymorphic markers. Eur J Hum Genet 2005;13:660-668
88. Kamal S, Turner B, He Q, et al. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology 2006;43:771-779
89. Poon TC, Hui AY, Chan HL, et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting. Clin Chem 2005;51:328-335
90. Callewaert N, Van Vlierbeghe H, Van Hecke A, et al. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004;10:429-434
91. Ishibashi K, Nishikawa A, Hayashi N, et al. N- acetylglucosaminyltransferase III in human serum, and liver and hepatoma tissues: increased activity in liver cirrhosis and hepatoma patients. Clin Chim Acta 1989;185:325-332
92. Kuroda Y, Nakata M, Makino A, et al. Structural studies on IgG oligosaccharides of patients with primary Sjogren's syndrome. Glycoconj J 2002;19:23-31
93. Pagliaro L, Rinaldi F, Craxi A, et al. Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis: a prospective, randomized trial. Dig Dis Sci 1983;28:39-43
94. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898-1906
95. Poniachik J, Bernstein DE, Reddy KR, et al. The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc 1996;43:568-571
96. Helmreich-Becker I, Schirmacher P, Denzer U, et al. Minilaparoscopy in the diagnosis of cirrhosis: superiority in patients with Child-Pugh A and macronodular disease. Endoscopy 2003;35:55-60